Apollo Endosurgery (APEN) Stock Price, News & Analysis

Company Overview

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Key Stats

• Today's Range: N/A
• 50-Day Range: $9.87 to $10.00
• 52-Week Range: N/A
• Volume: 1.66 million shs
• Average Volume: 1.43 million shs
• Market Capitalization: $579.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APEN Stock Analysis - Frequently Asked Questions

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its quarterly earnings data on Sunday, October, 31st. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to the consensus estimate of $16.20 million. Apollo Endosurgery had a negative net margin of 51.84% and a negative trailing twelve-month return on equity of 89.48%.

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apollo Endosurgery investors own include Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), Ocugen (OCGN), Canopy Growth (CGC), Inovio Pharmaceuticals (INO) and Meta Platforms (META).

Company Calendar

• Last Earnings: 10/31/2021
• Today: 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APEN
• CIK: 1251769
• Web: www.apolloendo.com
• Phone: (512) 279-5100
• Fax: 858-678-0900
• Employees: 202
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,840,000.00
• Net Margins: -51.84%
• Pretax Margin: -51.08%
• Return on Equity: -89.48%
• Return on Assets: -33.76%

Debt

• Debt-to-Equity Ratio: 1.04
• Current Ratio: 2.35
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $76.86 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 57,972,000
• Free Float: 47,943,000
• Market Cap: $579.72 million
• Optionable: Not Optionable
• Beta: 2.31